cyrilzakka/clinical-trials huggingface dataset:
Primary Care Clinical Practice Elements and Improving Overweight Children's Weight Status

The purpose of this study is to identify whether specific clinical practices-including attention to body-mass-index (BMI) screening/overweight/obesity, medical risk (from conditions associated with overweight/obesity such as high blood pressure), and following up to reassess progress-will improve the weight status of overweight school-age children.

The aim of this study is to identify specific clinical practice elements in pediatric primary care that predict improvement in weight status among overweight school-age children. Pediatricians are well-suited to regularly assess and treat school-age children who are overweight. Well-child visits present an important opportunity to assess and treat overweight children. Strategies are needed to maximize the effectiveness of this opportunity. Although the American Academy of Pediatrics endorses recommendations by the United States Preventive Services Task Force that clinicians screen for overweight, assess medical/behavior risk, and use a staged treatment approach that includes frequent reassessment, it is unclear whether these practices, when used in primary care, impact whether children make lifestyle changes or improve their weight status. It is essential to identify specific clinical practice elements and communication strategies associated with weight-status improvement in overweight children, to maximize the effectiveness of primary-care weight-management interventions. The investigators hypothesize that, during primary-care visits with overweight 6-12-year-old children, attention to high BMI, medical risk (from weight-related comorbidities such as high blood pressure), and reassessing progress (defined as having a primary-care visit with evidence of attention to BMI or completing a referral to a weight-management specialist or nutritionist) will be associated with improvement in weight status (assessed as decrease in percent overweight (percentage above the age/sex-specific 95th BMI percentile) at follow-up.

Eligibility Criteria:
Inclusion Criteria:

* 6-12 year-old children with ≥2 visits
* valid height and weight data at each visit
* BMI ≥85th percentile at the first visit

Exclusion Criteria:

* children \<6 and \>12 years old
* no valid height and weight data at two visits
* BMI \<85th percentile at all 6-12 year-old well child visits
Investigation of the Effect of Using "Curtain"

Thyroid nodules are among the common health problems in adulthood. Thyroid cancers account for approximately 1% of all malignancies in a year.The majority of cancers are diagnosed by thyroid fine needle aspiration biopsy. The most commonly diagnosed cancer type is papillary thyroid cancer and accounts for 85% of all thyroid cancers.Thyroid Ultrasonography is the most important imaging method used in the evaluation of the thyroid gland and its nodules. It enables the detection of nodules and their characteristics and plays a role in deciding which nodules should be evaluated with fine needle aspiration biopsy.Non-pharmacological treatment methods are interventions that can be used to reduce the side effects of medical, surgical or pharmacological treatments. By using medical treatment and complementary therapy together, nurses can reduce patients' anxiety, support their sleep, create a healing environment and increase their health level.

As a non-pharmacological strategy, distraction can be seen as a cost-effective approach to reduce anxiety in procedures that would cause negative anxiety and increase the opportunity for ease of operation. The curtain method also typically involves the use of visually interesting curtains or partitions that can be drawn around the patient's examination area. These curtains may have calming images or vibrant patterns that can help shift the patient's focus away from the frightening procedure being performed.

Research Type:

It was designed as a randomized controlled experimental study.

Research Population and Sample:

The research sample will consist of patients with suspected thyroid mass who applied to a City Training and Research Hospital. The sample of the study is expected to consist of 100 volunteer patients with suspected thyroid mass who applied to the hospital.

Eligibility Criteria:
Inclusion Criteria:

* Suspicion of a mass in the thyroid
* No vision problems

Exclusion Criteria:

* Mental health problems
Aripiprazole Treatment of Bipolar Depression

This is a study of addition of aripirazole to the treatment of bipolar depressed patients who are not better on the medications that they are currently receiving.

Hypothesis/Objectives:

Aim 1: To investigate whether aripiprazole is effective in the treatment of bipolar depression.

Hypothesis 1: Aripiprazole will lead to a significant decrease in scores on the Hamilton Depression Rating Scale (HAM-D) during an 8-week treatment course.

a. Study Population:

A total number of 10 evaluable patients will be enrolled in the study.

c. Study Design and Method

This proposal will use an open label design. Aripiprazole will be added to the treatment of patients with DSM-IV (American Psychiatric Association, 1994) BDD. Patients will be allowed to continue their psychotropic medication, at a stable dose, as long as they meet inclusion criteria as described below. Aripiprazole will be started at a dose of 10 mg for two weeks, 15 mg for an additional two weeks, and 20 mg for the last four weeks. The length of time a patient stays on the maximum dose (20 mg) depends upon the patient's tolerance and treatment response. Treatment will continue for 8 weeks with weekly visits and ratings on the 17-item Hamilton Depression Rating Scale (HAM-D 17) and other ratings scales.

Eligibility Criteria:
Inclusion Criteria:

* 1) Male or female between 18 - 65 years of age, inclusive 2) Satisfy DSM-IV criteria for bipolar disorder depressed phase i.e.,duration of depression \> 2 weeks) 3) No change in psychotropic medication or their doses within 2 weeks of inclusion in The study. 4) Inadequately responsive to or intolerant of prior pharmacotherapy as determined by the investigator 5) 17-item Hamilton Depression Rating Scale Score \> 15 6) Young Mania Rating Scale (Young, et. al., 1978) (YMRS) \< 10.

Exclusion Criteria:

Exclusion Criteria: 1) History of or currently suffering from serious medical illness, or be on medication that may interact with aripiprazole 2) On any other neuroleptic e.g., olanzapine, risperidone, ziprasidone, haloperidol.

3) History of substance abuse within 3 months or substance dependence within 6 months of the study. 4) Pregnant or planning to be pregnant or not using adequate contraception. 5) Received electroconvulsive therapy (ECT) treatment in the past 1 year. 6) Significant suicide or homicide risk at the time of the study; 7) Not on any herbal or any other alternative pharmacological treatment. 8) Renal or hepatic dysfunction 9) History of decreased sweating or heat stroke.

-
Role of Tyrosine Kinase Lyn and Cleaved Form by Caspases in Psoriasis

Psoriasis is a chronic autoimmune disorder of the skin. In this disease, the inflammatory caspases, cysteine proteases involved in the processing of many proteins, are activated. Transgenic mice expressing the cleaved form of caspases by Lyn, a tyrosine kinase Src family, develop an inflammatory syndrome with the characteristics of human psoriasis.

To clarify the relationship between the cleaved form of Lyn by caspases and psoriasis, the investigators intend to develop a clinical study to analyze the expression, cleavage and activity of Lyn and the activation of caspases from skin biopsies of patients with this disease.

This study will be conducted on a cohort of patients with different forms of psoriasis (plaque, pustular and erythrodermic) and atopic dermatitis, another skin disorder associated with chronic inflammation. Thus, the investigators will evaluate the expression and activity of Lyn from skin lesion (L) and non-lesional (NL) from the same patient in parallel with the level of caspase activation and apoptotic inflammatory.

Thus, the investigators will verify that the cleavage by caspases of Lyn is associated specifically with psoriasis, as the investigators believe, or more generally to the skin inflammation. The investigators work would then define the cleavage by caspases of Lyn as a new potential marker of human psoriasis.


Eligibility Criteria:
Inclusion Criteria:

Psoriasis arms:

* Plaque psoriasis and erythrodermic more than 10% of body surface area.
* Pustular psoriasis of at least 1% of body surface.

  * Atopic dermatitis arm:Patients with atopic dermatitis has been identified and inflammatory lesions on the skin.
  * Healthy arm:People not suffering from any skin disease

Exclusion Criteria:

* Systemic treatment of psoriasis for at least 4 weeks and / or local treatment for at least 2 weeks at the time of study entry.
* Patient with significant infection and / or immunocompromised.
Racial and Genetic Biomarkers of Response in Tissue Samples From Patients With Endometrial Cancer

This research study is studying racial and genetic biomarkers of response in tissue samples from patients with endometrial cancer. Studying samples of tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. DNA analysis of tumor tissue may also help doctors predict how well patients will respond to treatment.

PRIMARY OBJECTIVES:

I. To identify racial categorization as the proportion of genetic background of African-American or European-American women with endometrioid endometrial cancer (EEC).

II. To evaluate the association of racial genetic admixture with clinicopathologic variables and outcomes.

SECONDARY OBJECTIVES:

I. To compare the concordance between racial genetic admixture and self-designated race categorization.

OUTLINE: This is a multicenter study. Patients are stratified by race (African-American vs European-American) and disease stage (I vs II vs III vs IV).

DNA from archived frozen normal tissue samples is genotyped for the ancestry informative markers. Clinicopathological and demographic characteristics associated with each sample are also collected.

Eligibility Criteria:
Inclusion Criteria:

* Histologically confirmed endometrial cancer

  * Stage I-IV disease regardless of grade
  * Underwent surgical staging including hysterectomy, bilateral oophorectomy, washings, and pelvic lymphadenectomy
* Eligible and evaluated on GOG-0210 clinical trial, a Molecular Staging Study in Endometrial Cancer
* Available frozen or formalin-fixed and paraffin-embedded normal tissue that is free of tumor cells and yields sufficient high-quality normal DNA for testing
* Consented their specimens and clinical data to be collected and used in future studies
* Self-declared African-American or Caucasian race
SWiss Evaluation of Bioabsorbable Polymer-coated Everolimus-eluting Coronary sTent

Bioresorbable polymer drug eluting stents (DES) are an indisputable improvement over first-generation DES with promising results on long-term adverse events. But the thicker polymer and/or strut may hinder its deliverability. Complex procedures challenge stent deliverability and stent delivery failure impacts clinical prognosis.

This registry aimed to assess the immediate performance of the third-generation Synergy everolimus-eluting stent (sEES) and its 12-month clinical follow-up in an all-comer population.

All consecutive patients treated with the SYNERGY stent at our institutions were prospectively included in the SWEET registry. Baseline and procedural characteristics were collected at index procedure. Clinical follow-up was performed at 1 month and 1 year by clinic visit or follow-up call. The study end point was a composite of cardiac death (CD), myocardial infarction (MI) and target lesion revascularization (TLR) at 1 year.

Eligibility Criteria:
Inclusion Criteria:

1.Patient treated by everolimus-eluting SYNERGY® stent

Exclusion Criteria:

1. Patient or legal guardian won't give consent to use collected data
Improving Osteoporosis Care in a Home Health Setting

Study aims to improve osteoporosis care through patient tailored education materials in a group-randomized trial of patients referred to home health care with a history of fracture and/or an osteoporosis diagnosis. Project investigators will conduct telephone surveys and examine electronic medical record data to assess fracture related morbidity and mortality, osteoporosis treatment and adherence, and use of calcium and vitamin D supplements.

We hypothesize that patients that receive the intervention materials will be more likely to initiate or maintain osteoporosis treatment.


Eligibility Criteria:
Inclusion Criteria:

* prior fracture
* osteoporosis diagnosis
* received home health care

Exclusion Criteria:

* hospice
* active cancer treatment
The Effect of a Brief Intervention for Problem Gamblers

A pragmatic randomized pilot trial primarily examining the feasibility of a brief therapist guided online self-help program based on Cognitive behavioral therapy (CBT). Participants will be randomized to either a treatment as usual condition (TAU) or to TAU plus CBT.

The current study is a pragmatic randomized pilot trial examining the feasibility and effects of a brief therapist guided online self-help program based on Cognitive behavioral therapy (CBT) . Participants will be randomized to either a treatment as usual condition (TAU) or to TAU plus CBT.

Participants will be recruited via the Swedish national gambling helpline. After assessment for eligibility participants will be randomized, using block randomization to ensure balanced groups, to either TAU or TAU+CBT.

The participants will be measured; at baseline, weekly during the intervention (6 weeks), immediately after the intervention and at 6 weeks after treatment termination. Informed consent will be collected prior any data collection.

Eligibility Criteria:
Inclusion Criteria:

* ≥ 18 years
* Experiencing gambling problems (PGSI ≥ 3 p)
* Good enough knowledge in Swedish
* Access to a smart phone or computer with internet connection

Exclusion Criteria:

* Being involved in another treatment study the previous 3 months
* Other concurrent treatment for gambling problems
* Being on a non-stable pharmacological treatment for any psychiatric condition
* Severe depression defined as a PHQ-9 score of 20 points or more
Monitoring Arrhythmia Patients (IMPACT)

Prospective, multicenter, non-randomized study to determine the performance of NUVANT Mobile Cardiac Telemetry system in arrhythmia detection.

Arrhythmia patients will be externally monitored. The collected information will be used to evaluate the NUVANT MCT system.

Eligibility Criteria:
Inclusion Criteria:

* 18 years of age or older
* Patients undergoing remote ambulatory electrocardiographic monitoring

Exclusion Criteria:

* Is participating in another clinical study that may confound the results of this study
Effects of Face Masks on Cardiopulmonary Capacity in Healthy Individuals

The aim of our study is to compare the effects of face masks on cardiopulmonary capacity in young healthy individuals. The results of our study will show the effects of face masks commonly used during the pandemic period.

The aim of our study is to compare the effects of face masks on cardiopulmonary capacity in young healthy individuals. The results of our study will show the effects of face masks commonly used during the pandemic period.

The hypotheses we will test for this purpose; H1: face masks affect cardiopulmory capacity in healthy individuals H2: face masks affect heart rate in health individuals H3: face masks affect oxygen saturation in healthy individuals H4: face masks affect respiratory frequency in healthy individuals

Eligibility Criteria:
Inclusion Criteria:

* 18 years old to 30
* healthy young individuals

Exclusion Criteria:

* having cardiovasculary conditions
* having respiratory conditions
* having inflammatory conditions
* any contraindicated situations for cardiopulmonary tests
KN035 in Combination With Trastuzumab and Docetaxel in HER2-positive Breast Cancer

This is an open-label, single arm phase II trial to evaluate the efficacy, safety and tolerability of KN035 in combination with trastuzumab and docetaxel. Eligible patient will be enrolled and receive protocol defined therapies until progressive disease, unacceptable toxicity or withdrawal of informed consent. Tumor assessment will be performed according to RECIST 1.1 criteria.


Eligibility Criteria:
Inclusion Criteria:

* Written informed consent
* Female subjects with age 18 to 70 (inclusive) years at the time of consent
* LVEF ≥50% at baseline
* ECOG performance status of 0-1
* Have not received 1L treatment for recurrent or metastatic breast cancer
* Adequate organ function

Exclusion Criteria:

* History of exposure to the cumulative doses of doxorubicin \> 400 mg / m2 or equivalent
* History of autoimmune diseases
* Active brain metastasis
* Concurrent diseases that compromise patient's safety
Study Evaluating Tigecycline Versus Clindamycin Or Vancomycin On Complicated Skin And Skin Structure Infections Including Those Due To Methicillin-Resistant Staphylococcus Aureus (MRSA) In Pediatric Subjects

The main purpose of this study is to compare the safety and efficacy of tigecycline versus clindamycin (including subjects treated with vancomycin) in pediatric subjects (aged 8 to 17 years) with complicated skin and skin structure infections (cSSSI), including those caused by methicillin-resistant staphylococcus aureus (MRSA).


Eligibility Criteria:
Inclusion Criteria:

* Male or female subjects 8 to 17 years old. Children with bone maturation less than 8 years old should be enrolled with caution due to potential risk of tooth discoloration.
* Have a diagnosis of a serious infection requiring hospitalization and administration of IV antibiotic therapy.
* complicated skin and skin structure infections (cSSSI) requiring significant surgical intervention or involving deeper soft tissue with the presence of at least one sign of systemic infection

Exclusion Criteria:

* Subject with any concomitant illness/condition that, in the investigator's judgment, will substantially increase the risk associated with the subject's participation in and/or completion of the study, or could preclude the evaluation of the subject's response (e.g., life expectancy \< 30 days).
Protective Effects of Dexmedetomidine on Myocardial Injury During Liver Transplantation

The purpose of this study was to evaluate the protective effect of dexmedetomidine on myocardial injury during liver transplantation

Liver transplantation surgery may lead to myocardial injury. Dexmedetomidine, a highly specific α2-adrenoeptor agonist, has sedative and analgesic properties without significant respiratory depression at the clinically approved dosage. Some investigations indicated that dexmedetomidine was able to protect the myocardium via improving the activity of Na+-K+-adenosine triphosphate enzyme and Ca2+-adenosine triphosphate, alleviating inflammation reaction and avoiding Ca2+ overload. However, the effect and the mechanism of dexmedetomidine on myocardial injury during liver transplantation remain unclear.

Eligibility Criteria:
Inclusion Criteria:

* End stage liver disease scheduled for liver transplantation in Tianjin First Center Hospital

Exclusion Criteria:

* Pre-existing respiratory failure,renal failure,hepatic encephalopathy
Implications of a Paediatrician-psychologist Tandem for Sickle Cell Disease Care and Impact on Cognitive Functioning

Sickle cell disease (SCD) necessitates a paediatric treatment plan that considers the influence of psychological, family and intercultural factors. At the Louis-Mourier Hospital (APHP) in Colombes, France, a paediatric-psychological partnership where a clinical psychologist accompanies the paediatrician at programmed consultations was introduced.

The psychological repercussions of SCD were assessed among children and their parents treated in Colombes and in two other paediatric units without a paediatric-psychological partnership.


Eligibility Criteria:
Inclusion Criteria:

* Children under 18 years old
* Major form of SCD (SS, SC, Sβ° thal, Sβ+ thal) diagnosed by electrophoresis

Exclusion Criteria:

* Child or parent residing in France less than 6 months
* Having received SCD treatment in more than one centre
Study to Evaluate the Effectiveness of the Personal Pap Smear Device™ for Collection of Cervical Cells

This purpose of this research study is to determine the effectiveness of the Personal Pap Smear TM Device to collect adequate cervical cell samples for cytology examination when compared with the Rover Cervex-Brush (Cervix-Examination Brush).

To determine the effectiveness of the Personal Pap Smear TM Device to collect adequate (as defined by Bethesda Guidelines 2014) cervical cell samples for cytology examination as compared with the Rover Cervex-Brush (Cervix-Examination Brush).

Eligibility Criteria:
Inclusion Criteria:

* Adult women, aged 21-65 years old.
* Do not have any medical or psychiatric condition affecting the ability to give voluntary informed consent.
* Be able to read and understand English

Exclusion Criteria:

* Participants currently on menses
* Inability to provide Informed Consent
* Previous total hysterectomy
* History of radiation treatment for cervical cancer
* Pregnancy
* Medical condition that interferes with conduct of study, in investigator's opinion
* Evidence of active cervical infection requiring treatment
* Known bleeding diathesis
Improving Myoelectric Prosthetic and Orthotic Limb Control

The purpose of this study is to improve control of myoelectrically-controlled advanced orthotic devices (an exoskeleton device that use the body's muscle signals to drive movements of a robotic brace) by using advanced predictive decode algorithms, and the use of high count (\> 8) surface electromyographic (sEMG) electrodes.

This study looks to improve control of myoelectrically-controlled advanced powered orthoses (orthoses that use the body's muscle signals to drive movements of a robotic exoskeleton) by using advanced predictive decode algorithms, and the use of high count (\> 8) surface electromyographic (sEMG) electrodes.

Eligibility Criteria:
Inclusion Criteria:

* First-ever ischemic or hemorrhagic stroke
* Chronic Stroke (at least 6 months since onset)
* Chronic hemiparesis
* Functional range of motion for contralateral arm

Exclusion Criteria:

* Individuals who are currently Incarcerated